Vinay Prasad was reinstated as director of the FDA’s Center for Biologics Evaluation and Research (CBER) two weeks after his removal amid political controversy. His return elicited a muted market response for companies linked to the agency. Additionally, the FDA approved Thermo Fisher Scientific’s Oncomine Dx Target Test as a companion diagnostic for Boehringer Ingelheim’s newly approved lung cancer drug Hernexeos (zongertinib).